After 12 months of dupilumab therapy, no significant differences existed between those with and without NP regarding clinical (anosmia, ACT, and OCs use), laboratory (eosinophilic count, serum IgE level) parameters, and FEV1%. This evidence concerns the gene IGHE and Anosmia.